- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04325568
Developing Clinical Tools to Communicate Genetic Risk for Individuals Who Are Clinical High Risk for Psychosis
Developing Clinical Translational Tools to Communicate Genetic Risk Among Individuals Who Are at Clinical High Risk for Psychosis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10032
- New York State Psychiatric Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or females between the ages of 16- 30
- Current or previous COPE participant
- Identified as at clinical high risk for psychosis as defined as having at least one of the following: a)attenuated positive symptoms b)brief intermittent positive symptoms
Exclusion Criteria:
- Meeting CHR via only the Genetic risk and deterioration (GRD) syndrome. If the participant meets the GRD syndrome only, the investigators exclude the rare Genetic risk + deterioration (GRD) syndrome (comprising <1% of CHR cases) because GRD requires having a 1st degree relative with any psychotic disorder, which may be linked with stronger reactions to genetic framings.
- IQ < 80
- Inability to adopt hypothetical situation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Clinician Manual
Participants in the Clinician Manual arm will be introduced to a trained clinician and will complete one 60-minute session covering equivalent topics addressed in the PsyGist program. The manual will consist of: (1) a section exploring the youth's causal model for their high-risk state; (2) individualization per their causal model; and (3) tutorials that convey the main concepts of genetic malleability. Clinicians will assess individual causal models via discussion with CHR youth about their at- risk state. Individualization of genetic framing will occur using youths' causal models and will fall into 1 of 3 categories (per PsyGist): 'primarily genetic', 'primarily environmental' or 'combined'. |
This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis.
Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
|
Other: AutoTutor (PsyGist)
AutoTutor is an intelligent system that simulates talking with a human tutor. Our AutoTutor, called PsyGist, has 3 parts: (1) assessment of the youth's causal model for their high-risk state; (2) an individualized 'pre-tutorial' vignette matched to their causal model; (3) a 'tutorial' presenting the 'genetic malleability' framing. PsyGist will guide participants through its three components. |
This is a pre-post test design aimed at conveying future genetic risk information to those at clinical high risk for psychosis.
Participants will be assigned to either complete the Clinician Manual intervention (n= 27 participants) or PsyGist intervention (n=27 participants).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Perceived Treatment Efficacy
Time Frame: Baseline, immediately post-intervention, up to 30 minutes
|
Asks participants to rate the likelihood that engaging in treatment and adaptive behaviors will reduce the risk for developing psychosis, if they were told they had a genetic risk for psychosis.
Items are measured on a 4-point scale (1=very unlikely, 2=somewhat unlikely, 3=somewhat likely, 4=very likely), with higher scores indicating greater perceived efficacy.
Measure is divided into four sub-scales: a) avoiding unhealthy behaviors (4 items range 4-16), b) engaging in healthy behaviors (5 items range 5-20), c) utilizing specialized CHR services (3 items range 3-12), and d) help-seeking behaviors (6 items range 6-24).
Changes in scores from pre- to post-intervention are reported.
|
Baseline, immediately post-intervention, up to 30 minutes
|
Change From Baseline in Intention to Use Treatment
Time Frame: Baseline, Immediately post-intervention, up to 30 minutes
|
Asks participants to rate the likelihood of engaging in treatment and adaptive behaviors, if they were told they had a genetic risk for psychosis.
Items are measured on a 4-point scale (1=very unlikely, 2=somewhat unlikely, 3=somewhat likely, 4=very likely), with higher scores indicating greater intention.
The measure was divided into four sub-scales: a) avoiding unhealthy behaviors (4 items range 4-16), b) engaging in healthy behaviors (5 items range 5-20), c) utilizing specialized CHR services (2 items range 2-8), and d) help-seeking behaviors (6 items range 6-24).
Changes were measured pre- and post-intervention.
|
Baseline, Immediately post-intervention, up to 30 minutes
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline in Self-Stigma About Genetic Risk for Psychosis Development
Time Frame: Baseline, Immediately post-intervention, up to 30 minutes
|
Assess participants self-stigma if they were told they had a genetic risk for psychosis.
7 items are included: I believe I would be fundamentally different from most people (range 1-4), I would be more likely to do something violent towards other people (range 1-4), I would be more likely to do something violent towards myself (range 1-4), I would be more likely to be unpredictable (range 1-4), I would feel ashamed of myself (range 1-4), I would feel embarrassed about myself (range 1-4), I would think of myself as less competent (range 1-4).
each measured on a 4-point scale (1=strongly disagree, 2=somewhat disagree, 3=somewhat agree, 4=strongly agree), with higher scores indicating greater stigma.
Change in scores from pre- to post-intervention are reported.
|
Baseline, Immediately post-intervention, up to 30 minutes
|
Change in Anticipated Discrimination From Others Due to Genetic Risk for Psychosis Development
Time Frame: Baseline, Immediately post-intervention, up to 30 minutes
|
Assess participants anticipated discrimination if they were told they had a genetic risk for psychosis.
18 items (each with a range of 1-4) are measured on a 4-point scale (1=very unlikely, 2=somewhat unlikely, 3=somewhat likely, 4=very likely), with higher scores indicating greater anticipated stigma.
Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose however, this is based off a published discrimination scale (Wahl, 1999).
Change in scores from pre- to post-intervention for each item are reported.
|
Baseline, Immediately post-intervention, up to 30 minutes
|
Anticipated Rejection From Others Due to Genetic Risk for Psychosis Development
Time Frame: Baseline, Immediately post-intervention, up to 30 minutes
|
Assess participants anticipated rejection if they were told they had a genetic risk for psychosis.
3 items (each with a range of 1-4) measured on a 4-point scale (1=very unconcerned, 2=somewhat unconcerned, 3=somewhat concerned, 4=very concerned), with higher scores indicating greater anticipated rejection.
Because this is an exploratory R21 trial, the investigators are also testing and validating new measures for this specific group and purpose; however, these items are based off of a published rejection sensitivity scale (Link, Wells, Phelan, Yang, 2015).
Change in scores from pre- to post- intervention for each item are reported.
|
Baseline, Immediately post-intervention, up to 30 minutes
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Lawrence Yang, PhD, New York University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1R21HG010420 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psychosis
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingFirst Episode Psychosis (FEP) | Clinical High Risk for Psychosis (CHR)United States
-
University of UdineNational Research Council (CNR), Institute of Biomolecular Chemistry (ICB)...RecruitingClinical High Risk for Psychosis | Ultra High Risk for Psychosis | Attenuated Psychotic SymptomsItaly
-
University of New MexicoNational Institute of Mental Health (NIMH)CompletedPsychosis | Clinical High Risk for Psychosis | First Episode PsychosisUnited States
-
Chulalongkorn UniversityNational Research Council of Thailand; Thanyarak InstituteCompletedMethamphetamine-induced PsychosisThailand
-
Shanghai Jiao Tong University School of MedicineGuangzhou Psychiatric Hospital; Suzhou Psychiatric Hospital; Tianjin Anding Hospital and other collaboratorsRecruitingSchizophrenia; Psychosis | Clinical High Risk | First Episode PsychosisChina
-
University of California, San DiegoCenter for Medicinal Cannabis ResearchRecruitingEarly PsychosisUnited States
-
Yale UniversityCompleted
-
University of TorontoUniversity of British Columbia; Centre for Addiction and Mental Health; Queen... and other collaboratorsNot yet recruitingPsychotic Disorders | Schizophrenia | Psychosis | Schizophrenia; Psychosis
-
Northwell HealthNational Institute of Mental Health (NIMH)RecruitingFirst Episode PsychosisUnited States
-
State reference center for psychosocial careUniversity of ValenciaCompleted
Clinical Trials on PsyGist and Clinician Manual
-
University of MichiganNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Department...CompletedUpper Gastrointestinal BleedingUnited States
-
Northwestern UniversityCompletedObesity | Binge EatingUnited States
-
Fenway Community HealthPatient-Centered Outcomes Research Institute; Kaiser Permanente; Howard Brown... and other collaboratorsCompletedEducation | Gender Identity | Sexual Orientation | LGBT Health | Cultural CompetencyUnited States
-
VA Office of Research and DevelopmentEnrolling by invitationHeart Failure | Cancer | Chronic Obstructive Pulmonary Disease | Dementia | Interstitial Lung Disease | End-stage Renal Disease | Seriously Ill Patients | End-stage Liver DiseaseUnited States
-
Vanderbilt University Medical CenterSociety of Critical Care MedicineCompletedPost-Intensive Care SyndromeUnited States, Australia
-
St. Justine's HospitalUniversity of Maryland, College Park; Tokyo Women's Medical University; Tokyo... and other collaboratorsEnrolling by invitationAcute Respiratory Distress Syndrome | Medical Emergencies | Distress Respiratory Syndrome | Chemical Injury | Chemicals; IntoxicationCanada, France, Japan, United States
-
Children's Hospital of PhiladelphiaAgency for Healthcare Research and Quality (AHRQ)Completed
-
Research Foundation for Mental Hygiene, Inc.Montefiore Medical CenterTerminatedAlcohol Dependence | HIV/AIDSUnited States
-
Abramson Cancer Center at Penn MedicineNational Institute on Drug Abuse (NIDA); University of PennsylvaniaEnrolling by invitationSmoking | Tobacco Use | HIV | Nicotine DependenceUnited States
-
Abramson Cancer Center at Penn MedicineNational Cancer Institute (NCI); University of PennsylvaniaCompletedSmoking | Cancer | Tobacco Use | Nicotine DependenceUnited States